Last reviewed · How we verify
Acute decompensated heart failure in patients receiving diuretics
Approved treatments
- Milrinone Lactate · Pfizer Inc.
Phosphodiesterase-3 inhibitor that increases cardiac contractility and promotes vasodilation through cAMP elevation.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Acute decompensated heart failure in patients receiving diuretics patent landscape — cliff calendar, originator estates, attackable patents
- Acute decompensated heart failure in patients receiving diuretics treatment landscape brief
- Acute decompensated heart failure in patients receiving diuretics treatment updates RSS
Frequently asked questions about Acute decompensated heart failure in patients receiving diuretics
What drugs treat Acute decompensated heart failure in patients receiving diuretics?
Tracked treatments include Milrinone Lactate.
What is the treatment for Acute decompensated heart failure in patients receiving diuretics?
Standard treatment for Acute decompensated heart failure in patients receiving diuretics includes Milrinone Lactate. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Acute decompensated heart failure in patients receiving diuretics patent cliff · Acute decompensated heart failure in patients receiving diuretics CI report
- Treatment: Milrinone Lactate · Pfizer Inc.
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing